Work

Supplementary Figure S5 from Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC

Year: 2023
Type: supplementary-materials
Abstract: Survival outcomes according to KEAP1 and STK11 co-mutation status: A) Cohort A; B) Cohort B; C) further subclassifying KEAP1MUT tumors according to STK11 mutation status; D) PFS and OS according to STK11 co-mutation status in KSCWT tumors in the overall study cohort.
Language: English
Field: Medicine
Open Access status: gold
OpenAlex ID: W4383535784
Cites:
Cited by:
Related to: 10